RecruitingPhase 4

Aspirin and Preeclampsia

United States180 participantsStarted 2021-02-15

Plain-language summary

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pregnant Adults between 18 and 45 years of age
✓. Diagnosed with preeclampsia
✓. Presenting for delivery with a singleton gestation.

Exclusion criteria

✕. We will exclude patients in labor
✕. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
✕. Plan to deliver outside of the participating site
✕. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
✕. Aspirin allergy
✕. Clear indication for aspirin therapy or contraindication to aspirin therapy
✕. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
✕. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.

What they're measuring

Difference in Activin A levels

Timeframe: 6 Months

GLS percentages

Timeframe: 6 months

Trial details

NCT IDNCT04479072

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-01

Contact for this trial

Sajid Shahul, MD, PhD

773-398-2956 sshahul1@dacc.uchicago.edu

View on ClinicalTrials.gov More Preeclampsia Postpartum trials